Research programme: cyclo-oxygenase-2 inhibitors - Onconova

Drug Profile

Research programme: cyclo-oxygenase-2 inhibitors - Onconova

Alternative Names: COX-2 inhibitors research programme - Onconova; Cyclo-oxygenase-2 inhibitors research programme - Onconova; ON 09250; ON 09300; Onconoxib; Research programme: COX-2 inhibitors - Onconova

Latest Information Update: 23 Feb 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Onconova Therapeutics
  • Class Heterocyclic compounds
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Inflammation

Most Recent Events

  • 01 Jul 2004 Compounds from this programme are available for licensing (http://www.onconova.com/)
  • 01 Jul 2004 Preclinical trials in Cancer in USA (unspecified route)
  • 01 Jul 2004 Preclinical trials in Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top